CSF2 and malignant colon neoplasm: The GVAX colon vaccine is an allogeneic, whole-cell, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy that induces T cell immunity against a broad range of colon-cancer-associated antigens [184].